Our core technology was invented by Dr. Henrique De Paoli at Oak Ridge National Laboratory (ORNL). Dr. De Paoli’s goal was to create various combinations of DNA parts without having to pay for the synthesis — a common problem with existing technologies. He later found that this new technology, that he coined as TNT-cloning, improved cloning efficiencies by 10-fold and dramatically reduced build-times. Furthermore, upon testing by the Department of Energy’s Joint Genome Institute, TNT-cloning enabled a 2-fold increase in building of DNA constructs.
Co-Founder, Dr. Rob Moseley, recognized the potential of this technology and began working to build a company around it. In doing so, co-founders Ben Mohr and Jeremy Baldi and advisors Henrique De Paoli and Eric Mayer joined Dr. Moseley on the SimPath team.
Today, SimPath holds an exclusive license for this previously untapped technology, and has been awarded $250,000 R&D from ORNL. With additional improvements to the technology and IP acquisition, SimPath plans to offer both a DNA assembly service and kit for scientists and companies looking to outsource this type of work or bring our technology to their own lab.
TO MAKE AN
At SimPath, our mission is to offer scientists a way to improve productivity of designing and building synthetic DNA in order to produce next-gen pharmaceuticals, fuel, food and many other valuable products.
Jeremy brings the experience of building a company from the ground up to SimPath. Jeremy previously co-founded a medical staffing firm, Archway Physician Recruitment, with a focus on analytics. The firm is in its fifth year of operation and projects over $2.5M in revenue for the fiscal year. He oversaw the growth of the team to 14 members and also initiated the market expansion to include mid-level providers. Having received his Bachelor’s in Biology from Butler University, Jeremy has a capable scientific knowledge of SimPath’s products and services, in addition to his business expertise.
Rob Moseley, PhD
Rob came up with the idea of SimPath and works at the intersection of science and business to navigate SimPath to success. Rob received his PhD in Energy Science and Engineering through a joint program between the Bredesen Center at the University of Tennessee and Oak Ridge National Laboratory. Rob’s research is in the area of computational systems and Synthetic Biology
Ben brings his scientific knowledge of biomanufacturing to SimPath and helps guide R&D efforts for improving SimPath’s technology. Ben received his Bachelor’s in Biochemistry and Evolution & Ecology from The Ohio State University, and is now finishing his PhD at the University of Tennessee and Oak Ridge National Laboratory. His primary research focus is on applying cell-free synthetic biology for the discovery and characterization of natural products within the plant root microbiome.
Henrique Cestari De Paoli
Dr. De Paoli is a Senior Research Associate at the Department of Energy’s Joint Genome Institute at Lawrence Berkeley National Laboratory and is the inventor of SimPath’s core technology. Dr. De Paoli is a molecular biologist with broad expertise in bacteria, yeast, and plant-related synthetic biology tools. Dr. De Paoli received his PhD in Genetics from Universidade de São Paulo and completed post-docs at the University of California, San Diego and Oak Ridge National Laboratory. He brings extensive experience in the field of synthetic biology and provides valuable input in SimPath’s R&D efforts.
Eric is the CEO of EDP Biotech, a medical device company located in Knoxville, TN, and previously served as EDP Biotech’s VP of Business Development. Prior to EDP Biotech, Eric directed business development at BioPet Vet Lab and developed veterinary diagnostic products at AAD, Inc. He also has prior experience in biomedical/pharmaceutical start-ups, such as Metabolon, Inc. and Cirrus Pharmaceuticals. He received his Bachelor’s in Biochemistry from UNC-Chapel Hill, and his Master’s of Microbial Biotechnology and Master’s of Business Administration from NC State University. Eric brings significant experience in the biomedical and pharmaceutical industry and start-up business development.
Invest With SimPath
SimPath is currently looking for new customers and investors who share the same passion for our mission. We plan to be moved into our lab around late April – early May, and are excited for what’s ahead!